Matthew Beatty
@mbeattyphd.bsky.social
Cancer Immunologist | #TILTherapy Researcher | Avid traveler
Director, TIL Development Lab at Moffitt Cancer Center. @TILDevLab.bsky.social Views are my own.
#Immunology #Immunotherapy #Celltherapy #Immunosky
Director, TIL Development Lab at Moffitt Cancer Center. @TILDevLab.bsky.social Views are my own.
#Immunology #Immunotherapy #Celltherapy #Immunosky
Great thread Anna. Thanks for sharing this work.
November 27, 2024 at 9:30 PM
Great thread Anna. Thanks for sharing this work.
CEF for human samples. Will give reactivity on practically every sample.
November 26, 2024 at 7:18 PM
CEF for human samples. Will give reactivity on practically every sample.
Reposted by Matthew Beatty
Link to paper - Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients @mskcancercenter.bsky.social #CARTcells aacrjournals.org/clincancerre...
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
AbstractPurpose:. Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long-term adverse events, including second primary mal...
aacrjournals.org
November 23, 2024 at 9:04 PM
Link to paper - Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients @mskcancercenter.bsky.social #CARTcells aacrjournals.org/clincancerre...